BrainsWay Reports Open Market Stock Purchases by Two Board Members

BURLINGTON, Mass. and JERUSALEM, Nov. 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported that David Zacut, M.D., BrainsWay’s Chairman of the Board of Directors, and Avner Hagai, an independent Director on BrainsWay’s Board, separately purchased BrainsWay ordinary shares in recent open market purchases.

Dr. Zacut purchased 431,797 ordinary shares on the open market for a total amount of 1,607,676 NIS, at an average price of approximately 3.72 NIS per share. Following this transaction, he holds 6.71 percent of the Company’s total issued and outstanding shares.

Mr. Hagai purchased 403,312 ordinary shares on the open market for a total amount of 1,581,048 NIS, at an average price of approximately 3.92 NIS per share. Following this transaction, he holds 6.49 percent of the BrainsWay’s total issued and outstanding shares.

“These open market stock purchases are reflective of our continuing confidence in BrainsWay’s long-term prospects,” stated Dr. Zacut. “The Company has multiple growth catalysts ahead of it, and is further supported by favorable industry trends. Collectively, these key drivers present a highly compelling outlook for BrainsWay’s business.”

The share purchases were made on the Tel Aviv Stock Exchange, where the Company’s ordinary shares are listed and traded. The Company also trades in American Depositary Receipts (ADRs) on the Nasdaq, with each ADR representing two ordinary shares.

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit .

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Contacts:

BrainsWay:

Scott Areglado

SVP and Chief Financial Officer

844-386-7001

Investors:

Bob Yedid

LifeSci Advisors

646-597-6989